Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alogliptin + Metformin in T2DM
NCT00286442Phase 3Completed
- Sponsor
- Takeda
- Start
- Mar 2006
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of alogliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Takeda. Primary endpoint: Change From Baseline in Glycosylated Hemoglobin at 26 weeks. Started Mar 2006; status: completed.
02
Drugs
alogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00286442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00286442.